
AXSM • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
You don't hold AXSM in your mock portfolio yet.
Axsome Therapeutics remains unprofitable, as reflected in its negative EPS and PE ratio. The current earnings profile suggests ongoing cash burn and dependence on future growth and/or capital markets rather than internally generated profits. Until there is clearer visibility into a path to positive earnings, the fundamental earnings picture is a headwind for the stock.
The stock has shown strong recent momentum, rising 23.1% in the last month and trading well above its 200-day moving average. However, the RSI at 75.16 signals overbought conditions, suggesting elevated short-term risk of consolidation or pullback. Technically, the trend is strong but stretched, warranting caution at current levels.
Alternative data points suggest growing operational activity and increasing professional interest in Axsome Therapeutics. A sharp rise in job openings implies expansion and investment in growth, while LinkedIn follower growth indicates rising awareness and engagement in the healthcare and professional community. Web traffic and modest social media follower gains are supportive, though not yet explosive demand signals.
Axsome Therapeutics shows strong stock price momentum and positive alternative data signals, particularly in hiring and professional engagement, but its current lack of profitability and overbought technical condition temper the outlook. The setup appears to reflect high expectations for future growth rather than current financial strength. Overall, the balance of strong growth signals against earnings risk and a stretched chart supports a neutral stance at this time.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: